Korea vs Luxembourg: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Korea
97.0%
in 2025
Luxembourg
97.0%
in 2025
Korea rank
16th
Luxembourg rank
16th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Korea
- Luxembourg
How they compare
Korea currently reports 97.0% against 97.0% in Luxembourg, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Luxembourg ahead.
Korea ranks 16th and Luxembourg ranks 16th of 192 countries.
Across the 3 decades both report, Korea averaged higher in 1 and Luxembourg in 2.
Head to head by decade
| Decade | Korea | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 86.0% | 86.0% | Luxembourg |
| 2010s | 48.7% | 93.4% | 44.7% | Luxembourg |
| 2020s | 97.0% | 96.7% | 0.3% | Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Korea or Luxembourg?
- Korea, at 97.0% against 97.0% in Luxembourg as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Korea and Luxembourg?
- 0.0%, with Korea ahead.
- How many years of comparable data are there for Korea and Luxembourg?
- 18 years are reported by both, from 2008 to 2025.
- How do Korea and Luxembourg rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Korea ranks 16th and Luxembourg ranks 16th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.